Thermo Fisher Scientific Expands HeavyPeptide Collection, Offering Customers Greater Value and Choice

Source : Thermo Fisher Scientific Inc.

ULM, Germany (August 24, 2009) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it is expanding its industry-leading offering of HeavyPeptide kits for quantification of proteins through mass spectrometry. Providing customers with greater value and choice, the expanded Thermo Scientific HeavyPeptide Aqua™ line will debut at the 8th Annual World Congress of the Human Proteome Organisation (HUPO) in Toronto, Sept. 26-30. The collection includes:

  • HeavyPeptide AQUA Ultimate™ — the industry standard for absolute quantification, delivered in solution with known concentration and a precision level of +- 5 percent.

  • HeavyPeptide AQUA QuantPro™ — a more affordable alternative when ultimate precision is not necessary.

  • HeavyPeptide AQUA Basic — competitively priced and designed for customers engaged in relative quantification who prefer to work with lyophilized (powdered) products.

“With this expanded range of products, we are giving customers the choice of precision, grade and price,” said Joel Louette, commercial director for Thermo Scientific Custom Biopolymers.

In addition, the company continues to offer the Thermo Scientific HeavyPeptide™ FasTrack service to accelerate initial peptide selection and purification. The service provides customers with a choice of crude heavy peptides to develop their mass spectrometry assays and identify the best proteotypic peptide candidates. Once a customer has identified these candidates, retained crude stock is used to quickly produce the final purified heavy peptides to be used in the experiments. Crude heavy peptides are also now available independent of the FasTrack service.

The new HeavyPeptide AQUA offering will be exhibited during the HUPO Congress at Toronto’s Westin Harbour Castle. Members of the Thermo Scientific Custom Biopolymers team will be available to answer customer questions. While supplies last, vouchers for free HeavyPeptide AQUA sample kits will also be available.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With 2008 revenues of $10.5 billion, we have approximately 34,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. The Thermo Scientific brand represents a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit www.thermofisher.com.

###

  • <<
  • >>

Articles List

  • More than One Way to Change a Base

    More than One Way to Change a Base

    It’s easier than ever these days to clone and sequence DNA. Thanks to CRISPR/Cas and related technologies, it’s even straightforward to rewrite genomic sequences in living cells and organisms. But as powerful as it is, CRISPR, et al., cannot induce genetic rewrites in a test tube—genome editing requires cellular machinery to repair the DNA breaks the methods produce. Instead, researchers interested in mutating cloned genes on plasmids must revert to a tried-and-true method, site-directed mutagenesis. First described in the 1970s—and earning its inventor a share of the Nobel Prize in Chemistry in 1993—site-directed mutagenesis uses short oligonucleotides to introduce single base changes, as well as insertions and deletions, to DNA plasmids. Researchers can use the method to swap amino acids in expressed proteins, test clinically relevant mutations and tweak promoters. But there’s more than one way to change a base, and molecular-tools vendors have commercialized multiple strategies. Here, we review some of the more popular approaches to site-directed mutagenesis.
  • What Doesn’t Kill You … Testing for Chemical Toxicity

    What Doesn’t Kill You … Testing for Chemical Toxicity

    Understanding the effects of small molecules, compounds and chemicals on cells is the very core of drug discovery, one in which the pharmaceutical industry continues to invest billions of dollars. Yet alongside the question of whether such entities have a desired effect looms that of whether they have a toxic effect on those cells—and ultimately the tissues and organisms the cells compose. This question has equal importance to those who protect our environment and assure that our food is safe to eat. Testing chemical toxicity can take many forms, from looking for simple surrogates of death, such as the inability to exclude trypan blue, to sophisticated measures of changes in a specific cell type’s physiology. Various assays look at pathways leading to cell death, membrane integrity, depletion of energy, ability to proliferate and changes in differentiation. They are accomplished using instruments ranging from a hemocytometer and light microscope; to a Coulter counter, microplate reader or flow cytometer; to a high-content analysis solution found principally in screening cores at biotech and larger pharmaceutical companies. Screens for loss of viability are often the first line of inquiry, and only after an entity is shown to cause a decrease in survival is it then subjected to more nuanced assays [1]. Here we look at the principal means by which entities are tested for their effects on viability.

Disqus Comments